Subject: IC Materials
From: "John DeLoche" <[email-masked]>
To: "Hunter Biden" <[email-masked]>, "Devon Archer" <[email-masked]>, "Neil Callahan" <[email-masked]>, "William Lee" <[email-masked]>
Date: Sun, 9 Mar 2014 18:36:58 -0700

IC Committee,

In the interest of establishing a clear process for our investment
approvals I wanted to give you a preview of the agenda for the first IC
Committee call, which I hope we can do on our weekly call tmw. In the
future we will plan to have full memos distributed to the committee for
each deal the friday before the Monday committee meeting. Apologies we were
not able to put together a memo for Metabiota given our front end loading
of Lyft. We will put one together for Metabiota shortly.

We have three deals to discuss tmw.

The first is an increase in our investment in Metabiota by $250k. Docs are
attached. They raised about $2.4mm of which we represent $500k (250k from
the first investment plus this one). They intended to raise a max of $1.6mm
but it was oversubscribed. They way to think about this one is that
Palantir is the to the CIA what Metabiota is to the USDA. The company's
plan is to take advantage of the current fundraising climate and start
raising a series A as soon as this series seed closes. They hope to raise
another $15mm at at least $80mm pre which would be a nice 5x mark-up to our
investment. We are planning to show it to Founders Fund, Andreessen and
Google Ventures (among others) as potential leads.

The second is an investment in Lyft (doc attached)

The third is an increase in our investment in Counsyl. Goldman is going to
committee on Lyft and Counsyl on Tuesday.

Best,

John

John DeLoche
*Managing Director*
Rosemont Seneca Technology Partners
333 Bush Street, 21st Floor
San Francisco, CA 94104
office: 415 767 1288
mobile: 415 793 7070

This email communication is privileged and confidential and is intended
only for the individuals or entities named above. Any unauthorized
dissemination of any of the contents of this email is strictly prohibited.
If you are not the intended recipient, please do not read, copy, use or
disclose to others the contents of this communication. Please notify the
sender that you have received this e-mail in error and then delete the
e-mail